NORTH AMERICA SICKLE CELL DISEASE MARKET ANALYSIS

North America Sickle Cell Disease MarketSize and Trends

The North America sickle cell disease market is estimated to be valued at US$ 1,036.5 million in 2023 and is expected to exhibit a CAGR of 16.2% during the forecast period (2023-2030).

North America Sickle Cell Disease Market Segmentation:

The North America sickle cell disease market report is segmented into drug type, disease type, distribution channel.

• Based on disease type, the market is segmented into sickle cell anemia, sickle beta thalassemia, and sickle hemoglobin C disease. Out of which, sickle cell anemia is expected to hold a dominant position in the North America sickle cell disease market during the forecast period, and this is attributed to the increasing patient group in sickle cell disease.
• Based on drug type, the market is segmented into hydroxyurea, L-glutamine, crizanlizumab, pain-relievers, voxelotor, and others. Out of which, voxelotor is expected to dominate the market over the forecast period, and this is attributed to the higher efficacy in children aged 2 to 4 years with SCD.
• Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, the hospital pharmacies are expected to dominate the market over the forecast period, and this is attributed to the easy availability of drugs for the treatment of SCD.
• Among all the segmentation, the disease type segment is expected to dominate the market over the forecast period, and this is attributed to the positive results of the clinical trials. On June 26, 2022, Agios Pharmaceuticals Inc., a public U.S.-based pharmaceutical company pioneering therapies for genetically defined diseases with a near-term focus on developing therapies for hemolytic anemias, announced that the Phase 2 portion of the global Phase 2/3 RISE UP study of mitapivat in sickle cell disease met its primary endpoint of hemoglobin response. The results support proceeding with the Phase 3 portion of the study.

North America Sickle Cell Disease Market – Country Analysis

Among country, the U.S. is estimated to hold a dominant position in the North America sickle cell disease market over the forecast period. The U.S. is estimated to hold 91.3% of the market share in 2023. The U.S. sickle cell disease market is expected to witness significant growth in the coming years, driven by the high prevalence of sickle cell disease. Therefore, key players are focusing on developing breakthrough drug for the treatment of sickle cell disease. For instance, on June 24, 2020, IMARA Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, announced that the U.S. Food and Drug Administration (FDA) had granted Orphan Drug Designation for IMR-687 for the treatment of patients with beta-thalassemia. The U.S. FDA previously granted Orphan Drug Designation for IMR-687 for the treatment of patients with sickle cell disease.

North America Sickle Cell Disease Market: Key Trends

• A new technology platform is the key for market expansion: The advancement in the technology platform for the treatment of sickle cell disease is the key to market expansion over the forecast period. It is expected to improve the quality of life of patients and potentially provide a cure for the disease. This technological advancement has the potential to revolutionize the way sickle cell disease is managed, offering more effective and personalized treatment options. Additionally, it may also reduce the economic burden associated with long-term disease management, leading to improved healthcare outcomes for patients worldwide. For instance, on May 19, 2023, Tessera Therapeutics, a biotechnology company pioneering a new approach in genetic medicine known as Gene Writing, announced that the RNA Gene Writing platform demonstrated continued advances in rewriting to correct pathogenic mutations responsible for phenylketonuria (PKU), alpha-1 antitrypsin deficiency (AATD), and Sickle Cell Disease (SCD) including proof of concept in non-human primates (NHPs) for PKU.